casdozokitug (CHS-388)

P2, N=30, Completed, Coherus Oncology, Inc. | Active, not recruiting --> Completed | N=134 --> 30

P1, N=145, Completed, Coherus Oncology, Inc. | Active, not recruiting --> Completed | N=260 --> 145 | Trial completion date: Aug 2026 --> Jun 2025 | Trial primary completion date: Dec 2025 --> May 2025

P1, N=260, Active, not recruiting, Coherus Biosciences, Inc. | Recruiting --> Active, not recruiting

P2, N=134, Active, not recruiting, Coherus Biosciences, Inc. | Trial completion date: May 2026 --> Jun 2025

P2, N=72, Recruiting, Coherus Biosciences, Inc. | Not yet recruiting --> Recruiting

P2, N=72, Not yet recruiting, Coherus Biosciences, Inc.

P2, N=134, Active, not recruiting, Coherus Biosciences, Inc. | Trial completion date: Mar 2025 --> May 2026 | Trial primary completion date: Mar 2024 --> May 2025

P2, N=134, Active, not recruiting, Coherus Biosciences, Inc. | Recruiting --> Active, not recruiting

P1, N=260, Recruiting, Coherus Biosciences, Inc. | Trial completion date: May 2024 --> Aug 2026 | Trial primary completion date: May 2024 --> Dec 2025

Clinical Trial Registration Number NCT05359861 Sponsored by Surface Oncology Background: Casdozo is the first in class and only clinical-stage IL-27 targeting antibody, which neutralizes IL-27 in the tumor microenvironment and stimulates antitumor response. Triplet blockade of the IL-27, VEGF, and PD-(L)1 pathways with casdozo/atezo/bev has an acceptable safety profile to date with promising antitumor activity in uHCC that warrants continued exploration. Toxicity was consistent with the known profiles of the agents, with no new safety signals identified. Biomarker analysis to evaluate immune response and associations of IL-27 pathway and clinical outcomes is ongoing.

Blocking IL-27 activity by SRF388, a first-in-class monoclonal antibody, enhances immune function and demonstrates monotherapy activity in patients with cancer ( NCT04374877 )...IL-27 + cells are found in close proximity to PD-L1 + cells in patient tumors, and IL-27 can regulate levels of PD-L1 expression in immune cells and tumor cell lines, suggesting cross-talk between these molecules to diminish immune activation within the tumor microenvironment. Combined blockade of IL-27 and PD-(L)1 to enhance antitumor immune responses is currently being evaluated in clinical trials.

A Phase 1 trial of SRF388 (NCT04374877), a first-in-class anti–IL-27 antibody, has demonstrated monotherapy antitumor activity in a patient with non-small cell lung cancer (NSCLC).1 The current study aimed to characterize the immunoregulatory impact of IL-27 signaling by gene expression profiling...Conclusions These studies elucidate the transcriptional networks that are engaged after IL-27 signaling in immune and cancer cells and highlight the parallels with interferon-associated immune regulation. Blockade of IL-27 provides a novel therapeutic strategy to alleviate a gene transcriptional program implicated in immune suppression and checkpoint resistance.